|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SUSD4 |
Gene summary for SUSD4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SUSD4 | Gene ID | 55061 |
| Gene name | sushi domain containing 4 | |
| Gene Alias | PRO222 | |
| Cytomap | 1q41 | |
| Gene Type | protein-coding | GO ID | GO:0002250 | UniProtAcc | A0A140VK55 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55061 | SUSD4 | CCI_1 | Human | Cervix | CC | 6.93e-15 | 1.11e+00 | 0.528 |
| 55061 | SUSD4 | CCI_3 | Human | Cervix | CC | 1.74e-05 | 6.99e-01 | 0.516 |
| 55061 | SUSD4 | Tumor | Human | Cervix | CC | 1.46e-02 | 2.16e-01 | 0.1241 |
| 55061 | SUSD4 | sample3 | Human | Cervix | CC | 3.85e-07 | 2.58e-01 | 0.1387 |
| 55061 | SUSD4 | T3 | Human | Cervix | CC | 9.53e-08 | 2.51e-01 | 0.1389 |
| 55061 | SUSD4 | LZE2T | Human | Esophagus | ESCC | 2.66e-06 | 9.59e-01 | 0.082 |
| 55061 | SUSD4 | LZE5T | Human | Esophagus | ESCC | 2.30e-03 | 5.87e-01 | 0.0514 |
| 55061 | SUSD4 | LZE7T | Human | Esophagus | ESCC | 2.31e-02 | 1.23e-01 | 0.0667 |
| 55061 | SUSD4 | LZE8T | Human | Esophagus | ESCC | 4.02e-02 | 1.03e-01 | 0.067 |
| 55061 | SUSD4 | LZE20T | Human | Esophagus | ESCC | 3.21e-07 | 1.53e-01 | 0.0662 |
| 55061 | SUSD4 | LZE22T | Human | Esophagus | ESCC | 2.37e-04 | 5.44e-01 | 0.068 |
| 55061 | SUSD4 | LZE24T | Human | Esophagus | ESCC | 6.29e-07 | 2.22e-01 | 0.0596 |
| 55061 | SUSD4 | P1T-E | Human | Esophagus | ESCC | 3.41e-11 | 5.34e-01 | 0.0875 |
| 55061 | SUSD4 | P2T-E | Human | Esophagus | ESCC | 3.77e-02 | 8.25e-02 | 0.1177 |
| 55061 | SUSD4 | P4T-E | Human | Esophagus | ESCC | 6.97e-13 | 2.90e-01 | 0.1323 |
| 55061 | SUSD4 | P5T-E | Human | Esophagus | ESCC | 1.28e-26 | 5.75e-01 | 0.1327 |
| 55061 | SUSD4 | P8T-E | Human | Esophagus | ESCC | 1.07e-19 | 3.24e-01 | 0.0889 |
| 55061 | SUSD4 | P9T-E | Human | Esophagus | ESCC | 3.68e-14 | 3.44e-01 | 0.1131 |
| 55061 | SUSD4 | P10T-E | Human | Esophagus | ESCC | 3.71e-09 | 3.00e-01 | 0.116 |
| 55061 | SUSD4 | P12T-E | Human | Esophagus | ESCC | 8.71e-11 | 2.61e-01 | 0.1122 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00026837 | Cervix | CC | negative regulation of immune system process | 94/2311 | 434/18723 | 2.63e-08 | 1.87e-06 | 94 |
| GO:00028315 | Cervix | CC | regulation of response to biotic stimulus | 67/2311 | 327/18723 | 1.79e-05 | 3.36e-04 | 67 |
| GO:00022533 | Cervix | CC | activation of immune response | 72/2311 | 375/18723 | 8.26e-05 | 1.11e-03 | 72 |
| GO:00028322 | Cervix | CC | negative regulation of response to biotic stimulus | 27/2311 | 108/18723 | 2.27e-04 | 2.55e-03 | 27 |
| GO:00507773 | Cervix | CC | negative regulation of immune response | 41/2311 | 194/18723 | 3.63e-04 | 3.76e-03 | 41 |
| GO:00321022 | Cervix | CC | negative regulation of response to external stimulus | 75/2311 | 420/18723 | 5.96e-04 | 5.61e-03 | 75 |
| GO:00450882 | Cervix | CC | regulation of innate immune response | 44/2311 | 218/18723 | 6.40e-04 | 5.97e-03 | 44 |
| GO:00026983 | Cervix | CC | negative regulation of immune effector process | 26/2311 | 110/18723 | 7.40e-04 | 6.63e-03 | 26 |
| GO:00026973 | Cervix | CC | regulation of immune effector process | 62/2311 | 339/18723 | 9.25e-04 | 7.84e-03 | 62 |
| GO:00458243 | Cervix | CC | negative regulation of innate immune response | 18/2311 | 71/18723 | 2.01e-03 | 1.47e-02 | 18 |
| GO:0031348 | Cervix | CC | negative regulation of defense response | 48/2311 | 258/18723 | 2.30e-03 | 1.65e-02 | 48 |
| GO:00024603 | Cervix | CC | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 62/2311 | 356/18723 | 3.09e-03 | 2.03e-02 | 62 |
| GO:0002443 | Cervix | CC | leukocyte mediated immunity | 73/2311 | 440/18723 | 5.01e-03 | 2.98e-02 | 73 |
| GO:0002819 | Cervix | CC | regulation of adaptive immune response | 35/2311 | 183/18723 | 5.38e-03 | 3.11e-02 | 35 |
| GO:0002822 | Cervix | CC | regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 32/2311 | 168/18723 | 8.00e-03 | 4.18e-02 | 32 |
| GO:00069597 | Cervix | CC | humoral immune response | 54/2311 | 317/18723 | 8.57e-03 | 4.42e-02 | 54 |
| GO:00304492 | Cervix | CC | regulation of complement activation | 7/2311 | 21/18723 | 1.04e-02 | 4.97e-02 | 7 |
| GO:00028318 | Esophagus | ESCC | regulation of response to biotic stimulus | 191/8552 | 327/18723 | 2.12e-06 | 2.45e-05 | 191 |
| GO:000283212 | Esophagus | ESCC | negative regulation of response to biotic stimulus | 72/8552 | 108/18723 | 8.36e-06 | 8.11e-05 | 72 |
| GO:00450885 | Esophagus | ESCC | regulation of innate immune response | 125/8552 | 218/18723 | 3.34e-04 | 1.96e-03 | 125 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SUSD4 | SNV | Missense_Mutation | c.1294N>T | p.Ser432Cys | p.S432C | Q5VX71 | protein_coding | deleterious(0) | possibly_damaging(0.819) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SUSD4 | SNV | Missense_Mutation | rs756692002 | c.499G>A | p.Asp167Asn | p.D167N | Q5VX71 | protein_coding | tolerated(0.07) | benign(0.006) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SUSD4 | SNV | Missense_Mutation | c.1045G>A | p.Ala349Thr | p.A349T | Q5VX71 | protein_coding | tolerated(0.7) | benign(0) | TCGA-BH-A0BQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| SUSD4 | SNV | Missense_Mutation | rs774042536 | c.895N>G | p.Gln299Glu | p.Q299E | Q5VX71 | protein_coding | tolerated(0.28) | possibly_damaging(0.702) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
| SUSD4 | SNV | Missense_Mutation | c.545G>C | p.Arg182Thr | p.R182T | Q5VX71 | protein_coding | deleterious(0.01) | possibly_damaging(0.671) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SUSD4 | SNV | Missense_Mutation | rs750308474 | c.1141N>A | p.Glu381Lys | p.E381K | Q5VX71 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| SUSD4 | insertion | Frame_Shift_Ins | novel | c.254_255insTAAAGTGCTTACTTCTCCACGGAAGC | p.Gln86LysfsTer15 | p.Q86Kfs*15 | Q5VX71 | protein_coding | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | ||
| SUSD4 | SNV | Missense_Mutation | rs867759201 | c.800N>A | p.Gly267Glu | p.G267E | Q5VX71 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
| SUSD4 | SNV | Missense_Mutation | rs867759201 | c.800N>A | p.Gly267Glu | p.G267E | Q5VX71 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| SUSD4 | SNV | Missense_Mutation | c.1227N>C | p.Gln409His | p.Q409H | Q5VX71 | protein_coding | deleterious(0.01) | possibly_damaging(0.641) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |